← Back to headlines
Piper Upgrades Regeneron to Overweight on Dupixent and Pipeline Strength
Piper Sandler has upgraded Regeneron Pharmaceuticals to an 'overweight' rating, citing strong performance from its drug Dupixent and the potential of its robust pipeline.
31 Mar, 15:23 — 31 Mar, 15:23
Sources
Showing 1 of 1 sources
